Significance Statement {#s1}
======================

Dravet syndrome is a catastrophic childhood epilepsy that is resistant to available medications. Current animal models for this disease are not amenable to high-throughput drug screening. We used a zebrafish model for Dravet syndrome and screened \>1000 compounds. We report the identification of compounds with the ability to suppress seizure behavior and electrographic seizure activity. This approach provides an example of precision medicine directed to pediatric epilepsy.

Introduction {#s2}
============

Dravet syndrome (DS) is a devastating genetic epileptic encephalopathy that has been linked to more than \>300 *de novo* mutations in a neuronal voltage-gated sodium channel (*SCN*). Children with DS are at a higher risk for sudden unexplained death in epilepsy and episodes of uncontrolled status epilepticus ([@B17]; [@B10]). Delayed language development, disruption of autonomic function, and motor and cognitive impairment are also associated with this disease. Seizure management includes treatment with benzodiazepines, valproate, and/or stiripentol ([@B44]; [@B11]). Some reduction in seizure activity has been reported with the use of bromides and topiramate, or a ketogenic diet ([@B45]; [@B46]; [@B18]). Despite these options, available antiepileptic drugs (AEDs) do not achieve adequate seizure control in most DS patients ([@B17]; [@B11]; [@B18]), making the identification of new drugs a critical unmet need. High-throughput screening offers a powerful tool to identify new drug candidates for these patients. However, commonly available screening approaches rely on *in vitro* cell-based assays ([@B32]; [@B39]; [@B27]) and do not recapitulate the complicated neural networks that generate seizures *in vivo*. Given the need for new treatments for children with DS, and the growing number of genetic epileptic encephalopathies that are medically intractable ([@B29]; [@B20]; [@B34]), we developed an alternative phenotype-based *in vivo* drug-screening strategy. While cell-based *in vitro* screening assays can efficiently identify compounds that bind specific targets, whole-organism-based screens are more likely to reliably predict therapeutic outcomes as they maintain the complex neural circuitry involved in the underlying disease process. Whole-organism screens do not require well validated targets to identify compounds that yield a desirable phenotypic outcome, but can be prohibitively costly and time consuming in mammals. As a simple vertebrate with significant genetic similarity to human, zebrafish are now recognized as an ideal cost-effective alternative to achieve rapid *in vivo* phenotype-based screening ([@B1]).

Using *scn1a* mutant zebrafish larvae with a gene homologous to human and spontaneously occurring seizures ([@B3]), we screened, in a blinded manner, a repurposed library of ∼1000 compounds for drugs that inhibit unprovoked seizure events. We also screened two compounds (huperzine A and fenfluramine) that were discovered in rodent-based assays using acquired seizure protocols and that were recently suggested as potential treatments for DS ([@B9]; [@B13]; [@B10]; [@B8]). Only 20 compounds in the repurposed drug library reduced swim behavior to control levels. However, many of these compounds were toxic or were not confirmed on retesting, and only four compounds advanced to a second-stage *in vivo* electrophysiology assay. Of these compounds (cytarabine, dimethadione, theobromine, and norfloxacin) only dimethadione, a T-type calcium channel antagonist previously reported to have anticonvulsant activity ([@B30]; [@B43]), reduced ictal-like electrographic discharges seen in *scn1Lab* mutant larvae. This two-stage phenotype-based screening approach, using a genetic DS model with \>75% genomic similarity to human, is a sensitive, rapid means to successfully identify compounds with antiepileptic activity.

Materials and Methods {#s3}
=====================

Zebrafish {#s3A}
---------

Zebrafish were maintained in a light- and temperature-controlled aquaculture facility under a standard 14:10 h light/dark photoperiod. Adult zebrafish were housed in 1.5 L tanks at a density of 5-12 fish per tank and fed twice per day (dry flake and/or flake supplemented with live brine shrimp). Water quality was continuously monitored: temperature, 28-30º C; pH 7.4-8.0; conductivity, 690-710 mS/cm. Zebrafish embryos were maintained in round Petri dishes (catalog \#FB0875712, Fisher Scientific) in "embryo medium" consisting of 0.03% Instant Ocean (Aquarium Systems, Inc.) and 000002% methylene blue in reverse osmosis-distilled water. Larval zebrafish clutches were bred from wild-type (WT; TL strain) or *scn1Lab* (didy^s552^) heterozygous animals that had been backcrossed to TL wild-type for at least 10 generations. Homozygous mutants (*n* = 6544), which have widely dispersed melanosomes and appear visibly darker as early as 3 d postfertilization (dpf; [Fig. 1*b*](#F1){ref-type="fig"}), or WT larvae (*n* = 71) were used in all experiments at 5 or 6 dpf. Embryos and larvae were raised in plastic petri dishes (90 mm diameter, 20 mm depth) and density was limited to ∼60 per dish. Larvae between 3 and 7 dpf lack discernible sex chromosomes. The care and maintenance protocols comply with requirements outlined in the *Guide for the Care and Use of Animals* (ebrary Inc., 2011) and were approved by the Institutional Animal Care and Use Committee (protocol \#AN108659-01D).

![Locomotion assay to identify drugs that rescue the *scn1Lab* mutant epilepsy phenotype. ***a***, Schematic of the phenotype-based screening process. Chemical libraries can be coded and aliquoted in small volumes (75 µL) into individual wells containing one mutant fish. The 96-well microplate is arranged so that six fish are tested per drug; with one row of six fish maintained as an internal control (red circles) on each plate. ***b***, Representative images for WT and *scn1Lab* mutant zebrafish larvae at 5 dpf. Note the morphological similarity but darker pigmentation in mutant larvae. ***c***, Box plot of mean velocity (in millimeters per second) for two consecutive recordings of mutant larvae in embryo media. Experiments were performed by first placing the mutant larvae in embryo media and obtaining a baseline locomotion response; embryo media was then replaced with new embryo media (to mimic the procedure used for test compounds), and a second locomotion response was obtained. The percentage change in velocity from baseline (recording 1) versus experimental model (recording 2) is shown. In the box plot, the bottom and top of the box represent the 25th percentile and the 75th percentile, respectively. The line across the box represents the median value, and the vertical lines encompass the entire range of values. This plot represents normal changes in tracking activity in the absence of a drug challenge. ***d***, Plot of locomotor seizure behavior for *scn1Lab* mutants at 5 dpf for the 1012 compounds tested. Threshold for inhibition of seizure activity (positive hits) was set as a reduction in mean swim velocity of ≥44%; the threshold for a proconvulsant or hyperexcitable effect was set at an increase in the mean swim velocity of ≥44% (green dashed lines).](enu0041501060001){#F1}

Seizure monitoring {#s3B}
------------------

Zebrafish larvae were placed individually into 1 well of a clear flat-bottomed 96-well microplate (catalog \#260836, Fisher Scientific) containing embryo media. Microplates were placed inside an enclosed motion-tracking device and acclimated to the dark condition for 10-15 min at room temperature. Locomotion plots were obtained for one fish per well at a recording epoch of 10 min using a DanioVision system running EthoVision XT software (DanioVision, Noldus Information Technology); threshold detection settings to identify objects darker than the background were optimized for each experiment. Seizure scoring was performed using the following three-stage scale ([@B4]): Stage 0, no or very little swim activity; Stage I, increased, brief bouts of swim activity; Stage II, rapid "whirlpool-like" circling swim behavior; and Stage III, paroxysmal whole-body clonus-like convulsions, and a brief loss of posture. WT fish are normally scored at Stage 0 or I. Plots were analyzed for distance traveled (in millimeters) and mean velocity (in millimeters per second). As reported previously ([@B42]; [@B3]), velocity changes were a more sensitive assay of seizure behavior. For electrophysiology studies, zebrafish larvae were briefly paralyzed with α-bungarotoxin (1 mg/ml) and immobilized in 1.2% agarose; field recordings were obtained from forebrain structures. Epileptiform events were identified *post hoc* in Clampfit (Molecular Devices) and were defined as multispike or polyspike upward or downward membrane deflections greater than three times the baseline noise level and \>500 ms in duration. During electrophysiology experiments zebrafish larvae were continuously monitored for the presence (or absence) of blood flow and heart beat by direct visualization on an Olympus BX51WI upright microscope equipped with a CCD camera and monitor.

Drugs {#s3C}
-----

Compounds for drug screening were purchased from MicroSource Discovery Systems, Inc. (PHARMAKON 1600) and were provided as 10 m[m]{.smallcaps} DMSO solutions ([Table 1](#T1){ref-type="table"}). Test compounds for locomotion or electrophysiology studies were dissolved in embryo media and were tested at an initial concentration of 100 µ[m]{.smallcaps}, with a final DMSO concentration of \<2%. In all drug library screen studies, compounds were coded and experiments were performed by investigators who were blind to the nature of the compound. Baseline recordings of seizure behavior were obtained from mutants bathed in embryo media, as described above; a second locomotion plot was then obtained following a solution change to a test compound and an equilibration period of 15--30 min. Criteria for a positive hit designation were as follows: (1) a decrease in mean velocity of ≥44% (e.g., a value based on the trial-to-trial variability measured in control tracking studies; [Fig. 1*c*](#F1){ref-type="fig"}); and (2) a reduction to Stage 0 or Stage I seizure behavior in the locomotion plot for at least 50% of the test fish. Each test compound classified as a "positive hit" in the locomotion assay was confirmed, under direct visualization on a stereomicroscope, as the fish being alive based on movement in response to external stimulation and a visible heartbeat following a 60 min drug exposure. Toxicity (or mortality) was defined as no visible heartbeat or movement in response to external stimulation in at least 50% of the test fish. Hyperexcitability was defined as a compound causing a ≥44% increase in swim velocity and/or Stage III seizure activity in at least 50% of the test fish. Hits identified in the primary locomotion screen were selected from the PHARMAKON 1600 library and rescreened using the method described above. Select compound stocks that were successful in two primary locomotion assays, and were not classified as toxic in two independent clutches of zebrafish, were then purchased separately from Sigma-Aldrich for further testing. Drug concentrations between 0.5 and 1 m[m]{.smallcaps} were used for electrophysiology assays to account for more limited diffusion in agar-embedded larvae.

###### 

List of compounds from the PHARMAKON 1600 library used in this screen.

  --------------------------------------------
  ABACAVIR SULFATE
  ABAMECTIN (avermectin B1a shown)
  ACADESINE
  ACARBOSE
  ACEBUTOLOL HYDROCHLORIDE
  ACECLIDINE
  ACECLOFENAC
  ACENOCOUMAROL
  ACETAMINOPHEN
  ACETOHYDROXAMIC ACID
  ACETOPHENAZINE MALEATE
  ACETRIAZOIC ACID
  ACETYLCHOLINE CHLORIDE
  ACETYLCYSTEINE
  ACIPIMOX
  ACONITINE
  ACRIFLAVINIUM HYDROCHLORIDE
  ACRISORCIN
  ACTARIT
  ACYCLOVIR
  ADAPALENE
  ADELMIDROL
  ADENINE
  ADENOSINE
  ADENOSINE PHOSPHATE
  ADIPHENINE HYDROCHLORIDE
  AKLOMIDE
  ALAPROCLATE
  ALBENDAZOLE
  ALBUTEROL (+/-)
  ALENDRONATE SODIUM
  ALEXIDINE HYDROCHLORIDE
  ALLANTOIN
  ALLOPURINOL
  ALMOTRIPTAN
  alpha-TOCHOPHEROL
  alpha-TOCHOPHERYL ACETATE
  ALPRAZOLAM
  ALRESTATIN
  ALTHIAZIDE
  ALTRETAMINE
  ALVERINE CITRATE
  AMANTADINE HYDROCHLORIDE
  AMCINONIDE
  AMIFOSTINE
  AMIKACIN SULFATE
  AMILORIDE HYDROCHLORIDE
  AMINACRINE
  AMINOCAPROIC ACID
  AMINOGLUTETHIMIDE
  AMINOHIPPURIC ACID
  AMINOLEVULINIC ACID HYDROCHLORIDE
  AMINOSALICYLATE SODIUM
  AMITRIPTYLINE HYDROCHLORIDE
  AMLEXANOX
  AMLODIPINE BESYLATE
  AMODIAQUINE DIHYDROCHLORIDE
  AMOROLFINE HYDROCHLORIDE
  AMOXICILLIN
  AMPHOTERICIN B
  AMPICILLIN SODIUM
  AMPROLIUM
  AMSACRINE
  ANASTROZOLE
  ANCITABINE HYDROCHLORIDE
  ANETHOLE
  ANIRACETAM
  ANISINDIONE
  ANTAZOLINE PHOSPHATE
  ANTHRALIN
  ANTIPYRINE
  APOMORPHINE HYDROCHLORIDE
  APRAMYCIN
  ARGININE HYDROCHLORIDE
  ARMODAFINIL
  ARTEMETHER
  ARTEMOTIL
  ARTESUNATE
  ASCORBIC ACID
  ASPIRIN
  ATENOLOL
  ATORVASTATIN CALCIUM
  ATOVAQUONE
  ATROPINE SULFATE
  AUROTHIOGLUCOSE
  AVOBENZONE
  AZACITIDINE
  AZASERINE
  AZATADINE MALEATE
  AZATHIOPRINE
  AZELAIC ACID
  AZITHROMYCIN
  AZLOCILLIN SODIUM
  AZTREONAM
  BACAMPICILLIN HYDROCHLORIDE
  BACITRACIN
  BACLOFEN
  BALSALAZIDE DISODIUM
  BECLOMETHASONE DIPROPIONATE
  BEKANAMYCIN SULFATE
  BEMOTRIZINOL
  BENAZEPRIL HYDROCHLORIDE
  BENDROFLUMETHIAZIDE
  BENORILATE
  BENSERAZIDE HYDROCHLORIDE
  BENZALKONIUM CHLORIDE
  BENZETHONIUM CHLORIDE
  BENZOCAINE
  BENZOIC ACID
  BENZONATATE
  BENZOYL PEROXIDE
  BENZTHIAZIDE
  BENZYL ALCOHOL
  BENZYL BENZOATE
  BEPRIDIL HYDROCHLORIDE
  BERGAPTEN
  beta-CAROTENE
  BETAHISTINE HYDROCHLORIDE
  BETAINE HYDROCHLORIDE
  BETAMETHASONE
  BETAMETHASONE 17,21-DIPROPIONATE
  BETAMETHASONE VALERATE
  BETAMIPRON
  beta-NAPHTHOL
  BETAZOLE HYDROCHLORIDE
  BETHANECHOL CHLORIDE
  BEZAFIBRATE
  BICALUTAMIDE
  BIOTIN
  BISACODYL
  BISOCTRIZOLE
  BISORCIC
  BITHIONATE SODIUM
  BLEOMYCIN (bleomycin B2 shown)
  BRETYLIUM TOSYLATE
  BRINZOLAMIDE
  BROMHEXINE HYDROCHLORIDE
  BROMOCRIPTINE MESYLATE
  BROMPHENIRAMINE MALEATE
  BROXYQUINOLINE
  BUDESONIDE
  BUMETANIDE
  BUPIVACAINE HYDROCHLORIDE
  BUPROPION
  BUSULFAN
  BUTACAINE
  BUTAMBEN
  BUTOCONAZOLE
  CAFFEINE
  CAMPHOR (1R)
  CANDESARTAN
  CANDESARTAN CILEXTIL
  CANDICIDIN
  CANRENOIC ACID, POTASSIUM SALT
  CANRENONE
  CAPECITABINE
  CAPREOMYCIN SULFATE
  CAPSAICIN
  CAPTAMINE
  CAPTOPRIL
  CARBACHOL
  CARBENICILLIN DISODIUM
  CARBENOXOLONE SODIUM
  CARBETAPENTANE CITRATE
  CARBIDOPA
  CARBINOXAMINE MALEATE
  CARBOPLATIN
  CARISOPRODOL
  CARMUSTINE
  CARNITINE (dl) HYDROCHLORIDE
  CARPROFEN
  CARVEDILOL
  CEFACLOR
  CEFADROXIL
  CEFAMANDOLE NAFATE
  CEFAMANDOLE SODIUM
  CEFAZOLIN SODIUM
  CEFDINIR
  CEFEPIME HYDROCHLORIDE
  CEFMENOXIME HYDROCHLORIDE
  CEFMETAZOLE SODIUM
  CEFOPERAZONE
  CEFORANIDE
  CEFOTAXIME SODIUM
  CEFOTETAN
  CEFOXITIN SODIUM
  CEFPIRAMIDE
  CEFSULODIN SODIUM
  CEFTIBUTEN
  CEFTIOFUR HYDROCHLORIDE
  CEFTRIAXONE SODIUM TRIHYDRATE
  CEFUROXIME AXETIL
  CEFUROXIME SODIUM
  CELECOXIB
  CEPHALEXIN
  CEPHALOTHIN SODIUM
  CEPHAPIRIN SODIUM
  CEPHRADINE
  CETYLPYRIDINIUM CHLORIDE
  CHENODIOL
  CHLORAMBUCIL
  CHLORAMPHENICOL
  CHLORAMPHENICOL HEMISUCCINATE
  CHLORAMPHENICOL PALMITATE
  CHLORCYCLIZINE HYDROCHLORIDE
  CHLORHEXIDINE
  CHLOROCRESOL
  CHLOROGUANIDE HYDROCHLORIDE
  CHLOROQUINE DIPHOSPHATE
  CHLOROTHIAZIDE
  CHLOROXINE
  CHLOROXYLENOL
  CHLORPHENIRAMINE (S) MALEATE
  CHLORPROMAZINE
  CHLORPROPAMIDE
  CHLORPROTHIXENE HYDROCHLORIDE
  CHLORTETRACYCLINE HYDROCHLORIDE
  CHLORTHALIDONE
  CHLORZOXAZONE
  CHOLECALCIFEROL
  CHOLESTEROL
  CHOLINE CHLORIDE
  CICLOPIROX OLAMINE
  CILOSTAZOL
  CIMETIDINE
  CINCHOPHEN
  CINNARAZINE
  CINOXACIN
  CINTRIAMIDE
  CIPROFIBRATE
  CIPROFLOXACIN
  CISPLATIN
  CITALOPRAM HYDROBROMIDE
  CITICOLINE
  CLARITHROMYCIN
  CLAVULANATE LITHIUM
  CLEMASTINE
  CLIDINIUM BROMIDE
  CLINAFOXACIN HYDROCHLORIDE
  CLINDAMYCIN HYDROCHLORIDE
  CLIOQUINOL
  CLOBETASOL PROPIONATE
  CLOFARABINE
  CLOFIBRATE
  CLOMIPHENE CITRATE
  CLONIDINE HYDROCHLORIDE
  CLOPIDOGREL SULFATE
  CLORSULON
  CLOSANTEL
  CLOTRIMAZOLE
  CLOXACILLIN SODIUM
  CLOXYQUIN
  CLOZAPINE
  COENZYME B12
  COLCHICINE
  COLFORSIN
  COLISTIMETHATE SODIUM
  CORTISONE ACETATE
  COTININE
  CRESOL
  CROMOLYN SODIUM
  CRYOFLURANE
  CYCLAMIC ACID
  CYCLIZINE
  CYCLOBENZAPRINE HYDROCHLORIDE
  CYCLOHEXIMIDE
  CYCLOPENTOLATE HYDROCHLORIDE
  CYCLOPHOSPHAMIDE HYDRATE
  CYCLOSERINE (D)
  CYCLOSPORINE
  CYCLOTHIAZIDE
  CYPERMETHRIN
  CYPROTERONE ACETATE
  CYSTEAMINE HYDROCHLORIDE
  CYTARABINE
  DACARBAZINE
  DACTINOMYCIN
  DANAZOL
  DANTHRON
  DANTROLENE SODIUM
  DAPSONE
  DAPTOMYCIN
  DASATINIB
  DAUNORUBICIN
  DECIMEMIDE
  DEFEROXAMINE MESYLATE
  DEFLAZACORT
  DEHYDROACETIC ACID
  DEHYDROCHOLIC ACID
  DEMECLOCYCLINE HYDROCHLORIDE
  DERACOXIB
  DESIPRAMINE HYDROCHLORIDE
  DESOXYCORTICOSTERONE ACETATE
  DESVENLAFAXINE SUCCINATE
  DEXAMETHASONE
  DEXAMETHASONE ACETATE
  DEXAMETHASONE SODIUM PHOSPHATE
  DEXIBUPROFEN
  DEXLANSOPRAZOLE
  DEXPROPRANOLOL HYDROCHLORIDE
  DEXTROMETHORPHAN HYDROBROMIDE
  DIAVERIDINE
  DIBENZOTHIOPHENE
  DIBUCAINE HYDROCHLORIDE
  DICHLOROPHENE
  DICHLORVOS
  DICLAZURIL
  DICLOFENAC SODIUM
  DICLOXACILLIN SODIUM
  DICUMAROL
  DICYCLOMINE HYDROCHLORIDE
  DIENESTROL
  DIETHYLCARBAMAZINE CITRATE
  DIETHYLSTILBESTROL
  DIFLOXACIN HYDROCHLORIDE
  DIFLUNISAL
  DIGITOXIN
  DIGOXIN
  DIHYDROERGOTAMINE MESYLATE
  DIHYDROSTREPTOMYCIN SULFATE
  DILAZEP DIHYDROCHLORIDE
  DIMENHYDRINATE
  DIMERCAPROL
  DIMETHADIONE
  DIOXYBENZONE
  DIPHENHYDRAMINE HYDROCHLORIDE
  DIPHENYLPYRALINE HYDROCHLORIDE
  DIPYRIDAMOLE
  DIPYRONE
  DIRITHROMYCIN
  DISOPYRAMIDE PHOSPHATE
  DISULFIRAM
  DOBUTAMINE HYDROCHLORIDE
  DOCETAXEL
  DONEPEZIL HYDROCHLORIDE
  DOPAMINE HYDROCHLORIDE
  DOXEPIN HYDROCHLORIDE
  DOXOFYLLINE
  DOXYCYCLINE HYDROCHLORIDE
  DOXYLAMINE SUCCINATE
  DROFENINE HYDROCHLORIDE
  DROPERIDOL
  DROSPIRENONE
  DYCLONINE HYDROCHLORIDE
  DYPHYLLINE
  ECAMSULE TRIETHANOLAMINE
  ECONAZOLE NITRATE
  EDETATE DISODIUM
  EDITOL
  EDOXUDINE
  EMETINE
  ENALAPRIL MALEATE
  ENALAPRILAT
  ENOXACIN
  ENROFLOXACIN
  ENTACAPONE
  EPHEDRINE (1R,2S) HYDROCHLORIDE
  EPINEPHRINE BITARTRATE
  EPRINOMECTIN
  ERGOCALCIFEROL
  ERGONOVINE MALEATE
  ERYTHROMYCIN
  ERYTHROMYCIN ESTOLATE
  ERYTHROMYCIN ETHYLSUCCINATE
  ESCITALOPRAM OXALATE
  ESOMEPRAZOLE POTASSIUM
  ESTRADIOL
  ESTRADIOL BENZOATE
  ESTRADIOL CYPIONATE
  ESTRADIOL DIPROPIONATE
  ESTRADIOL VALERATE
  ESTRAMUSTINE
  ESTRIOL
  ESTRONE
  ESTROPIPATE
  ETHACRYNIC ACID
  ETHAMBUTOL HYDROCHLORIDE
  ETHAVERINE HYDROCHLORIDE
  ETHINYL ESTRADIOL
  ETHIONAMIDE
  ETHISTERONE
  ETHOPROPAZINE HYDROCHLORIDE
  ETHYL PARABEN
  ETODOLAC
  ETOPOSIDE
  EUCALYPTOL
  EUCATROPINE HYDROCHLORIDE
  EUGENOL
  EVANS BLUE
  EXEMESTANE
  EZETIMIBE
  FAMCICLOVIR
  FAMOTIDINE
  FAMPRIDINE
  FASUDIL HYDROCHLORIDE
  FEBUXOSTAT
  FENBENDAZOLE
  FENBUFEN
  FENDILINE HYDROCHLORIDE
  FENOFIBRATE
  FENOPROFEN
  FENOTEROL HYDROBROMIDE
  FENSPIRIDE HYDROCHLORIDE
  FEXOFENADINE HYDROCHLORIDE
  FIPEXIDE HYDROCHLORIDE
  FIROCOXIB
  FLOXURIDINE
  FLUCONAZOLE
  FLUDROCORTISONE ACETATE
  FLUFENAMIC ACID
  FLUINDAROL
  FLUMEQUINE
  FLUMETHASONE
  FLUMETHAZONE PIVALATE
  FLUNARIZINE HYDROCHLORIDE
  FLUNISOLIDE
  FLUNIXIN MEGLUMINE
  FLUOCINOLONE ACETONIDE
  FLUOCINONIDE
  FLUOROMETHOLONE
  FLUOROURACIL
  FLUOXETINE
  FLUPHENAZINE HYDROCHLORIDE
  FLURANDRENOLIDE
  FLURBIPROFEN
  FLUROFAMIDE
  FLUTAMIDE
  FLUVASTATIN
  FOLIC ACID
  FOSCARNET SODIUM
  FOSFOMYCIN CALCIUM
  FTAXILIDE
  FULVESTRANT
  FURAZOLIDONE
  FUROSEMIDE
  FUSIDIC ACID
  GABOXADOL HYDROCHLORIDE
  GADOTERIDOL
  GALANTHAMINE
  GALLAMINE TRIETHIODIDE
  GANCICLOVIR
  GATIFLOXACIN
  GEFITINIB
  GEMFIBROZIL
  GENTAMICIN SULFATE
  GENTIAN VIOLET
  GLIMEPIRIDE
  GLUCONOLACTONE
  GLUCOSAMINE HYDROCHLORIDE
  GLUTAMINE (D)
  GRAMICIDIN
  GRANISETRON HYDROCHLORIDE
  GRISEOFULVIN
  GUAIFENESIN
  GUANABENZ ACETATE
  GUANETHIDINE SULFATE
  HALAZONE
  HALCINONIDE
  HALOPERIDOL
  HEPTAMINOL HYDROCHLORIDE
  HETACILLIN POTASSIUM
  HEXACHLOROPHENE
  HEXYLRESORCINOL
  HISTAMINE DIHYDROCHLORIDE
  HOMATROPINE BROMIDE
  HOMATROPINE METHYLBROMIDE
  HOMOSALATE
  HYCANTHONE
  HYDRALAZINE HYDROCHLORIDE
  HYDRASTINE (1R, 9S)
  HYDROCHLOROTHIAZIDE
  HYDROCORTISONE
  HYDROCORTISONE ACETATE
  HYDROCORTISONE BUTYRATE
  HYDROCORTISONE HEMISUCCINATE
  HYDROCORTISONE PHOSPHATE TRIETHYLAMINE
  HYDROFLUMETHIAZIDE
  HYDROQUINONE
  HYDROXYAMPHETAMINE HYDROBROMIDE
  HYDROXYCHLOROQUINE SULFATE
  HYDROXYPROGESTERONE CAPROATE
  HYDROXYTOLUIC ACID
  HYDROXYUREA
  HYDROXYZINE PAMOATE
  HYOSCYAMINE
  IBANDRONATE SODIUM
  IBUPROFEN
  IDOXURDINE
  IDOXURIDINE
  IMIPRAMINE HYDROCHLORIDE
  IMIQUIMOD
  INAMRINONE
  INDAPAMIDE
  INDOMETHACIN
  INDOPROFEN
  INOSITOL
  IODIPAMIDE
  IODIXANOL
  IODOQUINOL
  IOHEXOL
  IOPANIC ACID
  IOTHALAMIC ACID
  IOVERSOL
  IOXILAN
  IPRATROPIUM BROMIDE
  IRBESARTAN
  ISONIAZID
  ISOPROPAMIDE IODIDE
  ISOPROTERENOL HYDROCHLORIDE
  ISOSORBIDE DINITRATE
  ISOSORBIDE MONONITRATE
  ISOTRETINON
  ISOXICAM
  ISOXSUPRINE HYDROCHLORIDE
  ITOPRIDE HYDROCHLORIDE
  IVERMECTIN
  KANAMYCIN A SULFATE
  KETOCONAZOLE
  KETOPROFEN
  KETOROLAC TROMETHAMINE
  KETOTIFEN FUMARATE
  LABETALOL HYDROCHLORIDE
  LACTULOSE
  LAMIVUDINE
  LANATOSIDE C
  LANSOPRAZOLE
  LEFLUNOMIDE
  LETROZOLE
  LEUCOVORIN CALCIUM
  LEVAMISOLE HYDROCHLORIDE
  LEVOCETIRIZINE DIHYDROCHLORIDE
  LEVOFLOXACIN
  LEVOMENTHOL
  LEVONORDEFRIN
  LEVONORGESTREL
  LEVOSIMENDAN
  LEVOTHYROXINE
  LIDOCAINE HYDROCHLORIDE
  LINCOMYCIN HYDROCHLORIDE
  LINDANE
  LINEZOLID
  LIOTHYRONINE
  LIOTHYRONINE (L- isomer) SODIUM
  LISINOPRIL
  LITHIUM CITRATE
  LOBELINE HYDROCHLORIDE
  LOFEXIDINE HYDROCHLORIDE
  LOMEFLOXACIN HYDROCHLORIDE
  LOMERIZINE HYDROCHLORIDE
  LOMUSTINE
  LORATADINE
  LORNOXICAM
  LOSARTAN
  LOVASTATIN
  LUMIRACOXIB
  MAFENIDE HYDROCHLORIDE
  MALATHION
  MANGAFODIPIR TRISODIUM
  MANIDIPINE HYDROCHLORIDE
  MANNITOL
  MAPROTILINE HYDROCHLORIDE
  MEBENDAZOLE
  MEBEVERINE HYDROCHLORIDE
  MEBHYDROLIN NAPHTHALENESULFONATE
  MECAMYLAMINE HYDROCHLORIDE
  MECHLORETHAMINE
  MECLIZINE HYDROCHLORIDE
  MECLOCYCLINE SULFOSALICYLATE
  MECLOFENAMATE SODIUM
  MECLOFENOXATE HYDROCHLORIDE
  MEDROXYPROGESTERONE ACETATE
  MEDRYSONE
  MEFENAMIC ACID
  MEFEXAMIDE
  MEFLOQUINE
  MEGESTROL ACETATE
  MEGLUMINE
  MELOXICAM SODIUM
  MELPERONE HYDROCHLORIDE
  MELPHALAN
  MEMANTINE HYDROCHLORIDE
  MENADIONE
  MEPARTRICIN
  MEPENZOLATE BROMIDE
  MEPHENESIN
  MEPHENTERMINE SULFATE
  MEPIVACAINE HYDROCHLORIDE
  MEQUINOL
  MERBROMIN
  MERCAPTOPURINE
  MEROPENEM
  MESNA
  MESO-ERYTHRITOL
  MESTRANOL
  METAPROTERENOL
  METARAMINOL BITARTRATE
  METAXALONE
  METHACHOLINE CHLORIDE
  METHACYCLINE HYDROCHLORIDE
  METHAPYRILENE HYDROCHLORIDE
  METHAZOLAMIDE
  METHENAMINE
  METHICILLIN SODIUM
  METHIMAZOLE
  METHOCARBAMOL
  METHOTREXATE(+/-)
  METHOXAMINE HYDROCHLORIDE
  METHOXSALEN
  METHSCOPOLAMINE BROMIDE
  METHYCLOTHIAZIDE
  METHYLBENZETHONIUM CHLORIDE
  METHYLDOPA
  METHYLERGONOVINE MALEATE
  METHYLPREDNISOLONE
  METHYLPREDNISOLONE SODIUM SUCCINATE
  METHYLTHIOURACIL
  METOCLOPRAMIDE HYDROCHLORIDE
  METOPROLOL TARTRATE
  METRONIDAZOLE
  MEXILETINE HYDROCHLORIDE
  MICONAZOLE NITRATE
  MIDODRINE HYDROCHLORIDE
  MIGLITOL
  MILNACIPRAN HYDROCHLORIDE
  MINAPRINE HYDROCHLORIDE
  MINOCYCLINE HYDROCHLORIDE
  MINOXIDIL
  MITOMYCIN C
  MITOTANE
  MITOXANTRONE HYDROCHLORIDE
  MOLSIDOMINE
  MONENSIN SODIUM (monensin A is shown)
  MONOBENZONE
  MORANTEL CITRATE
  MOXALACTAM DISODIUM
  MOXIFLOXACIN HYDROCHLORIDE
  MYCOPHENOLATE MOFETIL
  MYCOPHENOLIC ACID
  NABUMETONE
  NADIDE
  NADOLOL
  NAFCILLIN SODIUM
  NAFRONYL OXALATE
  NALBUPHINE HYDROCHLORIDE
  NALIDIXIC ACID
  NALOXONE HYDROCHLORIDE
  NALTREXONE HYDROCHLORIDE
  NAPHAZOLINE HYDROCHLORIDE
  NAPROXEN(+)
  NAPROXOL
  NATEGLINIDE
  NEFAZODONE HYDROCHLORIDE
  NEFOPAM
  NELARABIN
  NEOMYCIN SULFATE
  NEOSTIGMINE BROMIDE
  NEVIRAPINE
  NIACIN
  NICARDIPINE HYDROCHLORIDE
  NICERGOLINE
  NICLOSAMIDE
  NICOTINYL ALCOHOL TARTRATE
  NIFEDIPINE
  NIFURSOL
  NILUTAMIDE
  NIMODIPINE
  NITAZOXANIDE
  NITRENDIPINE
  NITROFURANTOIN
  NITROFURAZONE
  NITROMIDE
  NOCODAZOLE
  NOMIFENSINE MALEATE
  NOREPINEPHRINE
  NORETHINDRONE
  NORETHINDRONE ACETATE
  NORETHYNODREL
  NORFLOXACIN
  NORGESTREL
  NORTRIPTYLINE
  NOSCAPINE HYDROCHLORIDE
  NOVOBIOCIN SODIUM
  NYLIDRIN HYDROCHLORIDE
  NYSTATIN
  OCTOPAMINE HYDROCHLORIDE
  OFLOXACIN
  OLMESARTAN
  OLMESARTAN MEDOXOMIL
  OLSALAZINE SODIUM
  OLSELTAMIVIR PHOSPHATE
  OMEGA-3-ACID ESTERS (EPA shown)
  ONDANSETRON
  ORLISTAT
  ORPHENADRINE CITRATE
  OUABAIN
  OXACILLIN SODIUM
  OXALIPLATIN
  OXCARBAZEPINE
  OXETHAZAINE
  OXIBENDAZOLE
  OXIDOPAMINE HYDROCHLORIDE
  OXOLINIC ACID
  OXYBENZONE
  OXYMETAZOLINE HYDROCHLORIDE
  OXYPHENBUTAZONE
  OXYPHENCYCLIMINE HYDROCHLORIDE
  OXYQUINOLINE HEMISULFATE
  OXYTETRACYCLINE
  PACLITAXEL
  PALIPERIDONE
  PAPAVERINE HYDROCHLORIDE
  PARACHLOROPHENOL
  PARAROSANILINE PAMOATE
  PARGYLINE HYDROCHLORIDE
  PAROMOMYCIN SULFATE
  PAROXETINE HYDROCHLORIDE
  PEMETREXED
  PENCICLOVIR
  PENICILLAMINE
  PENICILLIN G POTASSIUM
  PENICILLIN V POTASSIUM
  PENTOLINIUM TARTRATE
  PENTOXIFYLLINE
  PERGOLIDE MESYLATE
  PERHEXILINE MALEATE
  PERICIAZINE
  PERINDOPRIL ERBUMINE
  PERPHENAZINE
  PHENACEMIDE
  PHENAZOPYRIDINE HYDROCHLORIDE
  PHENELZINE SULFATE
  PHENINDIONE
  PHENIRAMINE MALEATE
  PHENOLPHTHALEIN
  PHENTOLAMINE HYDROCHLORIDE
  PHENYL AMINOSALICYLATE
  PHENYLBUTAZONE
  PHENYLEPHRINE HYDROCHLORIDE
  PHENYLMERCURIC ACETATE
  PHENYLPROPANOLAMINE HYDROCHLORIDE
  PHENYTOIN SODIUM
  PHTHALYLSULFATHIAZOLE
  PHYSOSTIGMINE SALICYLATE
  PILOCARPINE NITRATE
  PIMOZIDE
  PINDOLOL
  PIOGLITAZONE HYDROCHLORIDE
  PIPERACETAZINE
  PIPERACILLIN SODIUM
  PIPERAZINE
  PIPERIDOLATE HYDROCHLORIDE
  PIPERINE
  PIPOBROMAN
  PIRACETAM
  PIRENPERONE
  PIRENZEPINE HYDROCHLORIDE
  PIROCTONE OLAMINE
  PIROXICAM
  PITAVASTATIN CALCIUM
  PIZOTYLINE MALATE
  POLYMYXIN B SULFATE
  POTASSIUM p-AMINOBENZOATE
  PRAMIPEXOLE DIHYDROCHLORIDE
  PRAMOXINE HYDROCHLORIDE
  PRASUGREL
  PRAZIQUANTEL
  PRAZOSIN HYDROCHLORIDE
  PREDNICARBATE
  PREDNISOLONE
  PREDNISOLONE ACETATE
  PREDNISONE
  PRILOCAINE HYDROCHLORIDE
  PRIMAQUINE DIPHOSPHATE
  PRIMIDONE
  PROADIFEN HYDROCHLORIDE
  PROBENECID
  PROBUCOL
  PROCAINAMIDE HYDROCHLORIDE
  PROCAINE HYDROCHLORIDE
  PROCARBAZINE HYDROCHLORIDE
  PROCHLORPERAZINE EDISYLATE
  PROCYCLIDINE HYDROCHLORIDE
  PROGESTERONE
  PROGLUMIDE
  PROMAZINE HYDROCHLORIDE
  PROMETHAZINE HYDROCHLORIDE
  PRONETALOL HYDROCHLORIDE
  PROPAFENONE HYDROCHLORIDE
  PROPANTHELINE BROMIDE
  PROPIOLACTONE
  PROPOFOL
  PROPYLTHIOURACIL
  PSEUDOEPHEDRINE HYDROCHLORIDE
  PUROMYCIN HYDROCHLORIDE
  PYRANTEL PAMOATE
  PYRAZINAMIDE
  PYRETHRINS
  PYRIDOSTIGMINE BROMIDE
  PYRILAMINE MALEATE
  PYRIMETHAMINE
  PYRITHIONE ZINC
  PYRONARIDINE TETRAPHOSPHATE
  PYRVINIUM PAMOATE
  QUETIAPINE
  QUINACRINE HYDROCHLORIDE
  QUINAPRIL HYDROCHLORIDE
  QUINESTROL
  QUINETHAZONE
  QUINIDINE GLUCONATE
  QUININE SULFATE
  QUIPAZINE MALEATE
  RACEPHEDRINE HYDROCHLORIDE
  RACTOPAMINE HYDROCHLORIDE
  RAMIPRIL
  RAMOPLANIN \[A2 shown; 2m[m]{.smallcaps}\]
  RANITIDINE
  RASAGILINE
  RESERPINE
  RESORCINOL
  RESORCINOL MONOACETATE
  RETAPAMULIN
  RETINOL
  RETINYL PALMITATE
  RIBAVIRIN
  RIFAMPIN
  RITANSERIN
  RITODRINE HYDROCHLORIDE
  RITONAVIR
  RIZATRIPTAN BENZOATE
  ROFECOXIB
  RONIDAZOLE
  ROPINIROLE
  ROSIGLITAZONE
  ROSUVASTATIN CALCIUM
  ROXARSONE
  ROXATIDINE ACETATE HYDROCHLORIDE
  ROXITHROMYCIN
  RUFLOXACIN HYDROCHLORIDE
  SACCHARIN
  SALICIN
  SALICYL ALCOHOL
  SALICYLAMIDE
  SALICYLANILIDE
  SALINOMYCIN, SODIUM
  SALSALATE
  SANGUINARINE SULFATE
  SCOPOLAMINE HYDROBROMIDE
  SELAMECTIN
  SEMUSTINE
  SENNOSIDE A
  SERATRODAST
  SERTRALINE HYDROCHLORIDE
  SEVOFLURANE
  SIBUTRAMINE HYDROCHLORIDE
  SILDENAFIL CITRATE
  SIMVASTATIN
  SIROLIMUS
  SISOMICIN SULFATE
  SODIUM DEHYDROCHOLATE
  SODIUM NITROPRUSSIDE
  SODIUM OXYBATE
  SODIUM PHENYLACETATE
  SODIUM PHENYLBUTYRATE
  SODIUM SALICYLATE
  SPARFLOXACIN
  SPARTEINE SULFATE
  SPECTINOMYCIN HYDROCHLORIDE
  SPIPERONE
  SPIRAMYCIN
  SPIRAPRIL HYDROCHLORIDE
  SPIRONOLACTONE
  STAVUDINE
  STREPTOMYCIN SULFATE
  STREPTOZOSIN
  SUCCINYLSULFATHIAZOLE
  SULBACTAM
  SULCONAZOLE NITRATE
  SULFABENZAMIDE
  SULFACETAMIDE
  SULFACHLORPYRIDAZINE
  SULFADIAZINE
  SULFADIMETHOXINE
  SULFAMERAZINE
  SULFAMETER
  SULFAMETHAZINE
  SULFAMETHIZOLE
  SULFAMETHOXAZOLE
  SULFAMETHOXYPYRIDAZINE
  SULFAMONOMETHOXINE
  SULFANILATE ZINC
  SULFANITRAN
  SULFAPYRIDINE
  SULFAQUINOXALINE SODIUM
  SULFASALAZINE
  SULFATHIAZOLE
  SULFINPYRAZONE
  SULFISOXAZOLE
  SULINDAC
  SULMAZOLE
  SULOCTIDIL
  SULPIRIDE
  SUPROFEN
  SURAMIN
  TACROLIMUS
  TAMOXIFEN CITRATE
  TANDUTINIB
  TANNIC ACID
  TAZOBACTAM
  TEGASEROD MALEATE
  TELMISARTAN
  TEMEFOS
  TEMOZOLAMIDE
  TENIPOSIDE
  TENOXICAM
  TERBUTALINE HEMISULFATE
  TERCONAZOLE
  TERFENADINE
  TESTOSTERONE
  TESTOSTERONE PROPIONATE
  TETRACAINE HYDROCHLORIDE
  TETRACYCLINE HYDROCHLORIDE
  TETRAHYDROZOLINE HYDROCHLORIDE
  TETROQUINONE
  THALIDOMIDE
  THEOBROMINE
  THEOPHYLLINE
  THIABENDAZOLE
  THIAMPHENICOL
  THIMEROSAL
  THIOGUANINE
  THIORIDAZINE HYDROCHLORIDE
  THIOSTREPTON
  THIOTEPA
  THIOTHIXENE
  THIRAM
  THONZONIUM BROMIDE
  THONZYLAMINE HYDROCHLORIDE
  TIAPRIDE HYDROCHLORIDE
  TIBOLONE
  TIGECYCLINE
  TILARGININE HYDROCHLORIDE
  TILETAMINE HYDROCHLORIDE
  TILMICOSIN
  TIMOLOL MALEATE
  TINIDAZOLE
  TOBRAMYCIN
  TODRALAZINE HYDROCHLORIDE
  TOLAZAMIDE
  TOLAZOLINE HYDROCHLORIDE
  TOLBUTAMIDE
  TOLMETIN SODIUM
  TOLNAFTATE
  TOLPERISONE HYDROCHLORIDE
  TOSYLCHLORAMIDE SODIUM
  TRANEXAMIC ACID
  TRANYLCYPROMINE SULFATE
  TRAZODONE HYDROCHLORIDE
  TRETINOIN
  TRIACETIN
  TRIAMCINOLONE
  TRIAMCINOLONE ACETONIDE
  TRIAMCINOLONE DIACETATE
  TRIAMTERENE
  TRICHLORMETHIAZIDE
  TRIFLUOPERAZINE HYDROCHLORIDE
  TRIFLUPROMAZINE HYDROCHLORIDE
  TRIFLURIDINE
  TRIHEXYPHENIDYL HYDROCHLORIDE
  TRILOSTANE
  TRIMEPRAZINE TARTRATE
  TRIMETHOBENZAMIDE HYDROCHLORIDE
  TRIMETHOPRIM
  TRIMETOZINE
  TRIMIPRAMINE MALEATE
  TRIOXSALEN
  TRIPELENNAMINE CITRATE
  TRIPROLIDINE HYDROCHLORIDE
  TRISODIUM ETHYLENEDIAMINE TETRACETATE
  TROLEANDOMYCIN
  TROPICAMIDE
  TROPISETRON HYDROCHLORIDE
  TRYPTOPHAN
  TUAMINOHEPTANE SULFATE
  TUBOCURARINE CHLORIDE
  TYROTHRICIN
  URACIL
  URAPIDIL HYDROCHLORIDE
  UREA
  URETHANE
  URSODIOL
  VALDECOXIB
  VALGANCICLOVIR HYDROCHLORIDE
  VALPROATE SODIUM
  VALSARTAN
  VANCOMYCIN HYDROCHLORIDE
  VENLAFAXINE
  VIDARABINE
  VINBLASTINE SULFATE
  VINORELBINE
  VINPOCETINE
  VIOMYCIN SULFATE
  VORICONAZOLE
  VORINOSTAT
  WARFARIN
  XYLAZINE
  XYLOMETAZOLINE HYDROCHLORIDE
  YOHIMBINE HYDROCHLORIDE
  ZALCITABINE
  ZAPRINAST
  ZIDOVUDINE \[AZT\]
  ZIPRASIDONE MESYLATE
  ZOMEPIRAC SODIUM
  ZOPICLONE
  --------------------------------------------

Data analysis {#s3D}
-------------

Data are presented as the mean and SEM, unless stated otherwise. Pairwise statistical significance was determined with a Student's two-tailed unpaired *t* test, ANOVA, or Mann--Whitney rank sum test, as appropriate, unless stated otherwise. Results were considered significant at *p* \< 0.05, unless otherwise indicated.

Results {#s4}
=======

A first-stage behavioral screen for antiepileptic activity {#s4A}
----------------------------------------------------------

Locomotion tracking is a reliable and rapid strategy with which to monitor behavioral seizures in freely swimming larval zebrafish ([@B4]; [@B42]). In these locomotion plots, high-velocity movements of ≥20 mm/s correspond to paroxysmal whole-body convulsions, referred to as Stage III, and are consistently observed in unprovoked *scn1Lab* mutant larvae but not in age-matched wild-type siblings. Using automated locomotion tracking, we performed a phenotype-based screen to identify compounds that significantly reduce mutant swim behavior to levels associated with Stage 0 or Stage I (e.g., activity equivalent to that seen in normal untreated WT zebrafish). In a 96-well format, we tracked mutant swim activity at baseline, and then again after addition of a test compound (100 µ[m]{.smallcaps}); each compound was tested on six individual mutant larvae ([Fig. 1*a*](#F1){ref-type="fig"}), and larvae were sorted based on pigmentation differences ([Fig. 1*b*](#F1){ref-type="fig"}). Mutant swim activity between two consecutive recording epochs in embryo media is tracked on every plate as an internal control. A box plot showing the change in swim velocity in untreated mutants is shown in [Figure 1*c*](#F1){ref-type="fig"} (*n* = 112) and defined as the control. Based on an SD of 21.8 for these data, we set the detection threshold as any compound that inhibits movement (measured as a change in mean velocity) by \>2 SDs (or ≥44%). This approach was previously validated using standard antiepileptic drugs in this model ([@B3]). Next, we screened a repurposed library in which all compounds have reached the clinical evaluation stage (PHARMAKON 1600 Collection; <http://www.msdiscovery.com/pharma.html>). Among the 1012 compounds screened ([Fig. 1*d*](#F1){ref-type="fig"}) only 20 (or 1.97%) were found to significantly inhibit spontaneous seizure behavior in *scn1Lab* mutants. All 20 compounds were subsequently retested in a separate clutch of *scn1Lab* mutants at a concentration of 100 µ[m]{.smallcaps} ([Fig. 2*a*](#F2){ref-type="fig"}, trial 2; *N* = 6 fish/compound). A total of 154 compounds were classified as "toxic" ([Table 2](#T2){ref-type="table"}); 55 compounds were classified as "hyperexcitable" ([Table 3](#T3){ref-type="table"}). Representative locomotion tracking raw data plots for gemfibrozil, a toxic nonsteroid nuclear receptor ligand, and mepivacaine, a hyperexcitable proconvulsant anesthetic, are shown in [Figure 2*b*](#F2){ref-type="fig"}.

![Positive hits identified in the locomotion assay. ***a***, Heat map showing the results of individual zebrafish trials (1-6) for compounds tested at a concentration of 100 µ[m]{.smallcaps} in the locomotion-tracking assay. Raw data values for individual fish are shown within the color-coded boxes for one sample trial. Mean velocity data are shown at right for "trial 1" and "trial 2"; six fish per trial. Note: only drugs highlighted in bold type were classified as positive nontoxic hits in two independent trials and moved on to further testing. ***b***, Representative raw locomotion data plots for six individual *scn1Lab* mutant larvae at baseline (top) and following the addition of a compound resulting in fatality (bottom, gemfibrozil) or hyperactivity (bottom, mepivacaine). Movement is color coded, with low-velocity movements shown in yellow, and high velocity movements shown in red.](enu0041501060002){#F2}

###### 

List of compounds exhibiting toxicity.

  ---------------------------------------
  ABACAVIR SULFATE
  ACIPIMOX
  ADENOSINE PHOSPHATE
  ALAPROCLATE
  AMLEXANOX
  AMOROLFINE HYDROCHLORIDE
  ANTAZOLINE PHOSPHATE
  ARTEMETHER
  ASCORBIC ACID
  ATORVASTATIN CALCIUM
  AUROTHIOGLUCOSE
  AZELAIC ACID
  BENORILATE
  BENZONATATE
  BETAINE HYDROCHLORIDE
  BETAMIPRON
  BROMHEXINE HYDROCHLORIDE
  BUDESONIDE
  BUPIVACAINE HYDROCHLORIDE
  BUSULFAN
  BUTOCONAZOLE
  CAPSAICIN
  CARPROFEN
  CEFORANIDE
  CEFOTAXIME SODIUM
  CEFOXITIN SODIUM
  CEPHALEXIN
  CHLORAMBUCIL
  CHLORAMPHENICOL HEMISUCCINATE
  CHLOROGUANIDE HYDROCHLORIDE
  CHLORPHENIRAMINE (S) MALEATE
  CINCHOPHEN
  CINNARAZINE
  CINTRIAMIDE
  CIPROFLOXACIN
  CLIDINIUM BROMIDE
  CLOZAPINE
  COLISTIMETHATE SODIUM
  CRYOFLURANE
  CYCLOPHOSPHAMIDE HYDRATE
  CYCLOTHIAZIDE
  CYPERMETHRIN
  DAUNORUBICIN
  DECIMEMIDE
  DEXTROMETHORPHAN HYDROBROMIDE
  DICHLOROPHENE
  DIETHYLCARBAMAZINE CITRATE
  DIOXYBENZONE
  DIRITHROMYCIN
  DISOPYRAMIDE PHOSPHATE
  DISULFIRAM
  ECONAZOLE NITRATE
  EDETATE DISODIUM
  EMETINE
  ENALAPRILAT
  ERYTHROMYCIN
  ETHINYL ESTRADIOL
  ETHIONAMIDE
  ETHOPROPAZINE HYDROCHLORIDE
  ETHYL PARABEN
  EUGENOL
  FIPEXIDE HYDROCHLORIDE
  FLUMETHASONE
  FLUNISOLIDE
  FLUVASTATIN
  GEMFIBROZIL
  GENTAMICIN SULFATE
  GLUCONOLACTONE
  HALAZONE
  HALCINONIDE
  HETACILLIN POTASSIUM
  HEXACHLOROPHENE
  HOMATROPINE METHYLBROMIDE
  HYDRASTINE (1R, 9S)
  HYDROXYAMPHETAMINE HYDROBROMIDE
  HYDROXYCHLOROQUINE SULFATE
  IODIXANOL
  IOHEXOL
  IRBESARTAN
  LEVOSIMENDAN
  LISINOPRIL
  LOMERIZINE HYDROCHLORIDE
  MANGAFODIPIR TRISODIUM
  MECLOFENOXATE HYDROCHLORIDE
  MESTRANOL
  METHACHOLINE CHLORIDE
  METHYLERGONOVINE MALEATE
  METRONIDAZOLE
  MIGLITOL
  MONENSIN SODIUM (monensin A is shown)
  MONOBENZONE
  MOXALACTAM DISODIUM
  NADOLOL
  NALBUPHINE HYDROCHLORIDE
  NALTREXONE HYDROCHLORIDE
  NAPHAZOLINE HYDROCHLORIDE
  NAPROXEN(+)
  NEOMYCIN SULFATE
  NIFEDIPINE
  NITAZOXANIDE
  NITROMIDE
  NORETHINDRONE
  OLMESARTAN MEDOXOMIL
  OXYMETAZOLINE HYDROCHLORIDE
  PARACHLOROPHENOL
  PAROMOMYCIN SULFATE
  PERHEXILINE MALEATE
  PHENTOLAMINE HYDROCHLORIDE
  PHENYLBUTAZONE
  PHENYLMERCURIC ACETATE
  PHYSOSTIGMINE SALICYLATE
  PIMOZIDE
  PIPERACILLIN SODIUM
  PIPERAZINE
  PIRACETAM
  PIRENZEPINE HYDROCHLORIDE
  PIROCTONE OLAMINE
  PITAVASTATIN CALCIUM
  PRIMAQUINE DIPHOSPHATE
  PROBENECID
  PROCARBAZINE HYDROCHLORIDE
  PROGLUMIDE
  PROMETHAZINE HYDROCHLORIDE
  PUROMYCIN HYDROCHLORIDE
  QUININE SULFATE
  RETINYL PALMITATE
  RIFAMPIN
  RITONAVIR
  ROFECOXIB
  RUFLOXACIN HYDROCHLORIDE
  SACCHARIN
  SALICIN
  SENNOSIDE A
  STAVUDINE
  STREPTOMYCIN SULFATE
  SULFADIAZINE
  SULINDAC
  SULOCTIDIL
  TANNIC ACID
  TELMISARTAN
  TENOXICAM
  THEOPHYLLINE
  TILETAMINE HYDROCHLORIDE
  TILMICOSIN
  TIMOLOL MALEATE
  TOLBUTAMIDE
  TOLNAFTATE
  TRAZODONE HYDROCHLORIDE
  TRETINOIN
  TRIFLUPROMAZINE HYDROCHLORIDE
  TROPISETRON HYDROCHLORIDE
  VALDECOXIB
  VORINOSTAT
  ZALCITABINE
  ---------------------------------------

###### 

List of compounds exhibiting hyperexcitable or proconvulsant activity.

  -----------------------------------
  ADENOSINE PHOSPHATE
  ALBUTEROL (+/-)
  ALEXIDINE HYDROCHLORIDE
  AMANTADINE HYDROCHLORIDE
  AMINOHIPPURIC ACID
  AMINOLEVULINIC ACID HYDROCHLORIDE
  AUROTHIOGLUCOSE
  AZACITIDINE
  BENZOYL PEROXIDE
  BETAZOLE HYDROCHLORIDE
  BROMHEXINE HYDROCHLORIDE
  BUSULFAN
  CEFSULODIN SODIUM
  CEFUROXIME AXETIL
  CHLOROGUANIDE HYDROCHLORIDE
  CYSTEAMINE HYDROCHLORIDE
  ECAMSULE TRIETHANOLAMINE
  ECONAZOLE NITRATE
  EDOXUDINE
  ENROFLOXACIN
  ESTRADIOL CYPIONATE
  ETHINYL ESTRADIOL
  ETHOPROPAZINE HYDROCHLORIDE
  ETOPOSIDE
  FASUDIL HYDROCHLORIDE
  FEBUXOSTAT
  FLUMETHASONE
  FLUOROMETHOLONE
  FURAZOLIDONE
  GANCICLOVIR
  GLUCONOLACTONE
  GRANISETRON HYDROCHLORIDE
  HALAZONE
  HEXACHLOROPHENE
  IODIPAMIDE
  LABETALOL HYDROCHLORIDE
  MEPIVACAINE HYDROCHLORIDE
  MITOXANTRONE HYDROCHLORIDE
  MORANTEL CITRATE
  NOCODAZOLE
  OFLOXACIN
  PENTOLINIUM TARTRATE
  PERINDOPRIL ERBUMINE
  PIOGLITAZONE HYDROCHLORIDE
  PRAMIPEXOLE DIHYDROCHLORIDE
  PROGLUMIDE
  RIFAMPIN
  SERATRODAST
  SERTRALINE HYDROCHLORIDE
  SIBUTRAMINE HYDROCHLORIDE
  SUCCINYLSULFATHIAZOLE
  TACROLIMUS
  TETROQUINONE
  TIMOLOL MALEATE
  URACIL
  -----------------------------------

A second-stage electrophysiology assay for antiepileptic activity {#s4B}
-----------------------------------------------------------------

Extracellular recording electrodes are a reliable, reproducible, and sensitive approach to monitor electroencephalographic activity in agar-immobilized larval zebrafish ([@B4]; [@B3]). Field electrodes offer high a signal-to-noise ratio and can be placed, using direct visualization in transparent larvae, into specific CNS structures (i.e., telencephalon or optic tectum). Using a local field electrode, we can efficiently monitor the occurrence of electrographic seizure events in the same zebrafish that were previously tested in the locomotion assay. Based on a positive nontoxic result in two independent locomotion assays, four drugs moved on to electrophysiology testing at concentrations between 500 µ[m]{.smallcaps} and 1 m[m]{.smallcaps} ([Fig. 3](#F3){ref-type="fig"}). Consistent with a "false-positive" classification, spontaneous epileptiform discharge activity was observed for three of these drugs: norfloxacin, theobromine, and cytarabine. Dimethadione, previously shown to inhibit spontaneous epileptiform discharges in thalamocortical slices at concentrations between 1 and 10 m[m]{.smallcaps} ([@B43]), suppressed burst discharge activity in *scn1Lab* mutant larvae ([Fig. 3*a*,*b*](#F3){ref-type="fig"}). To identify whether any of these four compounds exert nonspecific effects on behavior, they were also tested on freely swimming WT zebrafish larvae (5 dpf) at a concentration of 500 µ[m]{.smallcaps}. Comparing the total distance moved during a 10 min recording epoch before, and after, the application of a test compound failed to reveal any significant changes in locomotor activity ([Fig. 3*c*](#F3){ref-type="fig"}).

![Electrophysiology assay to identify drugs that rescue the *scn1Lab* mutant epilepsy phenotype. ***a***, Representative field electrode recording epochs (5 min in duration) are shown for the "positive" compounds identified in the locomotion assay. All recordings were obtained with an electrode placed in the forebrain of agar-immobilized *scn1Lab* larvae that was previously tested in the locomotion assay. A suppression of epileptiform electrographic discharge activity was noted in mutants exposed to dimethadione. ***b***, Bar plot showing the mean number of epileptiform events in a 10 min recording epoch for *scn1Lab* larvae exposed to cytarabine (*N* = 6), dimethadione (*N* = 6), theobromine (*N* = 6), and norfloxacin (*N* = 6). The mean ± SEM is shown. The fish shown were tested in the locomotion assay first. ***c***, Bar plot showing the total distance traveled before (black bars) and after (white bars) exposure to a test compound; 10 min recording epoch and six fish per drug. The mean ± SEM is shown.](enu0041501060003){#F3}

Assessment of huperzine A and fenfluramine for antiepileptic activity {#s4C}
---------------------------------------------------------------------

Next, we tested two additional compounds that were not in our drug library, but have recently been described as potential antiepileptic treatments for DS. Huperzine A, a small-molecule alkaloid isolated from Chinese club moss with NMDA-type receptor blocking and anticholinesterase activity, has purported antiepileptic actions against NMDA- or soman-induced seizures ([@B41]; [@B13]). In the locomotion assay, huperzine A failed to significantly alter *scn1Lab* seizure behavior at any concentration tested ([Fig. 4*a*,*b*](#F4){ref-type="fig"}). In contrast, huperzine A was effective at 1 m[m]{.smallcaps} in the acute pentylenetetrazole (PTZ) assay ([Fig. 4*b*](#F4){ref-type="fig"}). Fenfluramine is an amphetamine-like compound that has been reported to successfully reduce seizure occurrence in children with DS as a low-dose add-on therapy ([@B10]). In the locomotion assay, fenfluramine significantly reduced mutant mean swim velocity at concentrations between 100 and 500 μ[m]{.smallcaps} ([Fig. 4*c*,*d*](#F4){ref-type="fig"}); 1 m[m]{.smallcaps} fenfluramine was toxic in the *scn1Lab* and PTZ assays ([Fig. 4*d*](#F4){ref-type="fig"}). The fenfluramine-treated *scn1Lab* mutant exhibited a suppression of spontaneous electrographic seizure discharge to levels similar to controls at 500 μ[m]{.smallcaps}, but only a partial reduction in electrographic activity at 250 μ[m]{.smallcaps} ([Fig. 4*e*](#F4){ref-type="fig"}).

![Evaluation of putative antiepileptic drugs in *scn1Lab* mutants. ***a***, Locomotion tracking plots for *scn1Lab* zebrafish at baseline and following huperzine A administration. Total movement is shown for a 10 min recording epoch. ***b***, Plot showing the change in mean velocity for three different huperzine A concentrations (blue bars). Each bar is the mean change for six fish. The threshold for a positive hit is shown as a dashed line. WT fish exposed to PTZ and huperzine A are shown in red (*N* = 7). ***c***, ***d***, Same for fenfluramine. Note that 1 m[m]{.smallcaps} fenfluramine was toxic, as indicated. ***e***, Representative field recordings from *scn1Lab* mutant larvae at 5 dpf. Electrographic activity is shown for a 5 min recording epoch (top traces); high-resolution traces are shown below, as indicated. Note that abnormal burst discharge activity persists in *scn1Lab* mutants exposed to 250 µ[m]{.smallcaps} fenfluramine. The fish shown were tested in the locomotion assay first.](enu0041501060004){#F4}

Discussion {#s5}
==========

Zebrafish and humans share extensive genomic similarity. With regard to disease, 84% of genes known to be associated with disease states in humans have a zebrafish homolog ([@B25]). This genetic similarity and the characteristic of zebrafish larvae to exhibit quantifiable seizure behaviors or electrographic seizure discharge that is fundamentally similar to that recorded in humans ([@B26]) make this an ideal system for drug discovery. Behavioral assays customized for automated evaluation of locomotion ([@B42]; [@B14]; [@B6]; [@B3]; [@B35]) make moderate-to-high-throughput phenotype-based drug screening in zebrafish possible. Using this approach and a zebrafish *scn1* mutant ([@B3]), we successfully identified antiepileptic compounds. Here we report results from screening ∼1000 compounds from a repurposed drug library and present data that will be periodically updated on-line using this open-access publishing mechanism.

As a model system, the *scn1Lab* mutant zebrafish has many advantages. First, in contrast to transient and variable knockdown of gene expression using antisense morpholino oligonucleotides ([@B40]; [@B22]; [@B31]), *scn1Lab* mutants carry a stable and heritable amino acid substitution at position 1208 in the third domain of *SCN1A* that shares 76% homology with humans ([@B38]; [@B3]). Mutations in this channel are one of the primary genetic causes underlying DS ([@B12]; [@B21]; [@B16]; [@B37]). As zebrafish possess two *scn1* genes ([@B33]), homozygous mutants for *scn1Lab* are comparable to the haploinsufficient clinical condition, and there is no variability from larvae to larvae, or clutch to clutch, with respect to gene inactivation, as is commonly observed with morpholino injections ([@B28]). Although crosses of heterozygotes produce only one-quarter homozygous *scn1Lab* mutants per mating, there are virtually no limitations on maintaining a large colony of healthy, adult breeders for these types of large-scale screens. Second, it is possible to observe and monitor seizure-like behavior consisting of rapid movements and whole-body convulsions in freely swimming *scn1Lab* mutants as early as 4 dpf that persist for the life of the larvae (∼12 dpf). These behaviors are comparable to those observed with exposure to a common convulsant agent (PTZ) and classified as Stage III ([@B4]). In addition, clear evidence for epileptiform discharge generated in the CNS of immobilized *scn1Lab* mutant larvae has been obtained at ages between 4 and 8 dpf ([@B3]). Both zebrafish measures of seizure activity are sensitive to inhibition by AEDs commonly prescribed to children with DS (e.g., valproate, benzodiazepines, and stiripentol), but are resistant to many antiepileptic compounds (e.g., phenytoin, carbamazepine, ethosuximide, decimemide, tiletamine, primidone, phenacemide, and vigabatrin). Pharmacoresistance is defined as the inability to control seizure activity with at least two different AEDs ([@B7]), and, with demonstrated resistance to eight AEDs, our model clearly fits this definition. This level of model validation has not been possible with morpholinos probably owing to the high degree of variability, or off-target effects, associated with this technique ([@B28]).

Our screening results highlight the stringency of our approach with a positive hit rate of only 1.97% on the first-stage locomotion assay, and successful identification of 1 compound (of 1012 compounds) with known antiepileptic activity (i.e., dimethadione, a T-type channel antagonist). In additional testing, we confirmed an antiepileptic action for fenfluramine (serotonin uptake inhibitor). Similar to ethosuximide, a reduction in regenerative burst discharges associated with neuronal T-type calcium currents could be the underlying mechanism for dimethadione in DS mutants; however, it is worth noting that T-type channel blockers ethosuximide and flunarizine were not similarly effective ([@B3]; this article), and that dimethadione can cause arrhythmia owing to blockade of cardiac human ether-a-go-go-related gene potassium channels ([@B2]; [@B15]). Modulation of serotonin \[5-hydroxytryptamine (5-HT)\] signaling by blocking uptake or increasing release from neurons by acting as substrates for 5-HT transporter (sertraline) proteins ([@B23]; [@B24]; [@B5]; [@B36]) may be the mechanism of action for fenfluramine in patients with DS, though a detailed analysis of precisely how fenfluramine modulates excitability via this signaling pathway has not been performed. Nonetheless, both drugs probably exert a direct effect on network excitability (at neuronal or synaptic levels, respectively) to suppress electrographic discharge and the associated high-velocity seizure behavior seen in *scn1Lab* mutants, and may be potential targets for clinical use. In contrast, three other drugs identified in the primary locomotion assay were not effective in suppressing electrical events and were designated as false positives. This is not altogether surprising given that the xanthine alkaloid (theobromine), chemotherapeutic (cytarabine), and antibiotic (norfloxacin) mechanisms for these compounds would not be consistent with seizure inhibition. Moreover, the variability inherent in behavioral experiments performed on different zebrafish larvae, in different microplates, and on different days may contribute to these false-positive designations in locomotion assays, and is evident in the range of mean velocity values seen during tracking episodes from control studies ([Fig. 1*c*](#F1){ref-type="fig"}) or in the failure of many of the initial 20 lead compounds to be confirmed on subsequent retesting (see [Fig. 2*a*](#F2){ref-type="fig"}). This is a limitation of locomotion-based screening assays and is another reason why a secondary electrophysiology assay on the same zebrafish is a critical advantage of our approach.

An additional advantage of *in vivo* screening with zebrafish larvae is the simultaneous identification of compounds resulting in toxicity. Zebrafish-based anticonvulsant drug-screening assays based primarily on *in situ* hybridization detection of early gene expression at 2 dpf ([@B6]) do not routinely monitor spontaneous swim behavior, heart rate, or response to external stimuli. Lacking these real-time measures of toxicity, compounds observed to induce fatality in a freely swimming *scn1Lab*-based behavioral assay (e.g., gemfibrozil, suloctidil, pimozide, or dioxybenzone) were mistakenly classified as seizure-suppressing compounds in the PTZ-based c-Fos *in situ* hybridization assay. Indeed, 41% of the "anticonvulsant" compounds positively identified at 2 dpf in [@B6] were toxic, proconvulsant, or simply not effective in *scn1Lab* mutant assays at 5-6 dpf. Similarly, it is critical to monitor blood flow and heart activity even in the agar-immobilized electrophysiology assay as compounds effective in suppressing electrical activity can also be toxic. These discrepancies highlight the potential problems associated with zebrafish drug-screening strategies that do not encompass multiple readouts and suggest the need for a note of caution when comparing screening results from different laboratory groups. While any lead compound identified in a zebrafish-based screening assay will, ultimately, need to be independently replicated and/or validated in additional mammalian model systems, the ability to rapidly identify such compounds, while simultaneously identifying potential negative side effects, makes genetically modified zebrafish a unique resource for drug discovery in an age of personalized medicine.
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Synthesis {#s6}
=========

The decision was a result of the Reviewing Editor Elizabeth Powell and the peer reviewers coming together and discussing their recommendations until a consensus was reached. A fact-based synthesis statement explaining their decision and outlining what is needed to prepare a revision is listed below. The following reviewers agreed to reveal their identity: Karen Wilcox, Rosane Da Silva

Synthesis

The manuscript describes a high throughput study in which a zebrafish model of Dravet syndrome is uses to screen more than 1000 compounds in the search for new drugs for treatment in human patients. The reviewers stated strong enthusiasm for the work and the potential for advancing the field of human epilepsy and new therapeutic compounds. The format of the eNeuro journal is appropriate, as the data sets can be later updated to include new findings. Publishing all the data, the effective and ineffective or harmful compounds, is an important resource for the field.

Some major and minor issues were raised by the reviewers. These issues should be addressed prior to the manuscript being considered for publication. The reviewers\' comments follow.

Reviewer \#1

This is a well described, effective screen that has identified a number of potential anti-seizure drugs (ASDs) that may be efficacious for the treatment of Dravet\'s syndrome and other types of epilepsy. This approach should streamline ASD discovery and provide the field with useful positive and perhaps more importantly, negative results (so as to not waste time and effort on ineffective compounds). There are some issues that should be addressed.

Major concern:

There seems to be considerable variability in trial to trial effectiveness of compounds (e.g. Figure 3, with a stated 4/20 compounds showing comparable reductions in movement velocity from trial 1 to trial 2). The authors are to be commended for performing independent validation of each trial. However, the variability is not discussed in the context of being a limitation of this approach. Also, the threshold for considering whether a compound is indeed a positive hit is not well described. For example it is not clear why Theobromine was considered a hit in Fig 3, but Tolnaftate and Artemether was not. These issues should be discussed.

Minor Concerns:

In Figure 4, it would be helpful to provide baseline recording segments prior to the administration of compounds, especially any that prove efficacious (e.g. dimethadione).

In the discussion, towards the end of the second paragraph, the author states \"\...and successful identification of two compounds\.....and fenfluramine\". However, in the results section, it was mentioned that fenfluramine was not part of the original screen but was tested as a consequence of cited literature. In the discussion, the way that sentence is phrased, it sounds like fenfluramine was found in the screen of the library.

Figure 2 is somewhat confusing. At what point is it determined that velocity and distance are not correlated. It is unclear why the drugs selected were plotted, as none were viewed as significant hits. Also, as a positive hit needed to demonstrate \>44% reduction in velocity, it is not clear why estradiol was not considered a positive hit? Were the 5 drugs in part B part of the library?

Reviewer \#2

This manuscript describes a large-scale drug screening to identify antiepileptic drugs based in locomotor activity and electroencephalography registration using zebrafish. The study is well conducted and its publication will be a huge contribution to the use of zebrafish as a model to investigate antiepileptic properties and a contribution to the study of refractory epilepsy. While I am enthusiastic about the results of this manuscript, my enthusiasm became a little bit vanished while reading the text. In this way, I strongly recommend a careful revision of the text, especially in relation to the points mentioned below:

Major points:

1\. While the methodological approach is one of the main contributions of the study the authors do not discuss the results on the perspectives of the disease. The authors should contextualize the results in the end of the abstract and through the discussion session in order to show how the drugs identified could contribute to the study of the Dravet Syndrome.

2\. Also, the authors do not discuss the findings on the mechanistic level of the drugs identified with antiepileptic properties.

3\. On the introduction, the authors should enrich this session with data from the Dravet syndrome, treatments available\...

4\. There is an important problem in the distribution of the text through the sessions. There are elements of material and methods, results and discussion sessions on the introduction. There is lot of comments in the material and methods results sessions that should be avoided or transferred to the discussion session. The material and methods should not include results (e.g: last sentence of Drugs subtitle). The result session is exclusively to the results reached from this specific study, please delete comments, justifications,\...

5\. The material and methods session is very poorly written and there are several methodological information through the others sessions. See examples below:

5.1 What is the guideline used to base the animal care?

5.2 What conditions the animals were maintained (temperature, pH, conductivity, light/dark conditions, density, tanks dimension, 96 wells plate \...)?

5.3 The age of larvae during the seizure monitoring experiments is lacking (this information appears just in the legend of the figure 1)

5.4 How the heart beating and blood flow were registered?

5.5 How the animals were exposed to the drugs? How long was the exposition? Is the 15-30 minutes of equilibration period the time of exposure?

5.6 Was the final DMSO concentration in the electrophysiology experiments the same of locomotor experiments?

5.7 The concept of \"% changes in the mean velocity\" should be stated in the material and methods and not in the result session.

5.8 The criteria to define a drug as \"toxic\" should be stated in the material and methods and not in the result session.

5.9 Please, explain the criteria to consider a drug as an anticonvulsant or a proconvulsant at the material and methods and not at the results session.

5.10 Please, was the mortality registered?

6\. In the results session, the authors mentioned that the animals were sorted based on the pigmentation. What were the parameters considered? Please, at least mention that in the material and methods session.

7\. Also in the results session, the authors should show the results of heart beat and blood flow, since at the discussion they mentioned that as an important data to avoid misunderstandings on the interpretation of data. This would help to differentiate the animals from gemfibrozil (Figure 3b) from fenfluramine (figure 5c), since the first was fatal and the second not.

8\. The figures should include the data from WT animals and not just the mutant at the free-drug condition (locomotion and electrophysiology data).

9\. At figure 1d, it is hard to identify the \"1.97%\" of compounds at the figure 1. The figure is a little bit crowded.

10\. At the figure 4, why just 3 animals were used to the electrophysiology assay (cytarabine, theobromine and norfloxacin) since the locomotor assay was performed with 6 animals?

11\. Why the statistic of the results is not shown in the figures? For example, it is hard to identify how the authors differentiated the groups at the figure 2.

12\. Why the raw data were show just to the first trial?

Minor points:

1\. Please, avoid the words very little, higher, increased swimming, when the basal data is not available. If possible, show the real data.

2\. There are no figures 1e or 3c. Please, correct to 1d and 3b.

3\. Please, organize the legend of figure 5, there is some repetition.

4\. Why sometimes the total number of drugs is 1012, sometimes 1013, 1014..?
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